Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data.

ABSTRACT:

Introduction

Immunotherapy represents a key pillar of cancer treatments, with high response rates and long survival. Its use is increasing, mainly at the expense of the geriatric population due to the ageing of this population. However, despite its benefit, its safety in certain areas such as cardiotoxicity is largely unknown. The aim of this study is to assess the safety of immunotherapy in elderly patients using real-world data.

Methods

This is an ambispective study of patients ≥ 70 years old with solid tumours who were treated with immunotherapy at the University Hospital of Salamanca. Cardiotoxicity was assessed using the CTCAEv5.0 criteria.

Results

In total, 195 patients were included (76.9% male and 23.1% female), with a mean age of 75 years [70-93]. The percent

SUBMITTER: Toribio-Garcia I 

PROVIDER: S-EPMC10486692 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature